Skip to main content
. 2024 Feb 12;67(4):2305–2320. doi: 10.1021/acs.jmedchem.3c02239

Figure 9.

Figure 9

Comparison of the percentage of achiral, single enantiomer, and racemic NMEs/NASs (excluding biologics) approved by the FDA and EMA from 2013 to 2022.